Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Circulation

• Publication date

  1998-11-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.98.21.2248PMID 9826310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease

  2004cited by this paper
• Human Tissue Plasminogen Activator

  2000cited by this paper
• Expression of Plasminogen Activator Inhibitor Type I in Genotyped Human Endothelial Cell Cultures: Genotype-specific Regulation by Insulin

  1999cited by this paper
• Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells.

  1997cited by this paper
• Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells.

  1995cited by this paper
• Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients.

  1995influential reference
• The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. Sandoz/CVIS Investigators.

  1995influential reference
• The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study

  1995cited by this paper
• Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury.

  1995cited by this paper
• Evolution of Antibodies Anti-PF4/heparin in a Patient with a History of Heparin-induced Thrombocytopenia Reexposed to Heparin

  1994cited by this paper
• Effects of Metformin and Metoprolol CR on Hormones and Fibrinolytic Variables during a Hyperinsulinemic, Euglycemic Clamp in Man

  1994cited by this paper
• Retinoic acid effects on endothelial cell function: interaction with interleukin 1.

  1994cited by this paper
• Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease.

  1994cited by this paper
• Plasminogen Activator Inhibitor 1 and Atherothrombosis

  1993cited by this paper
• The fibrinolysis and coagulation systems in ischaemic heart disease. Risk markers and their relation to metabolic dysfunction of the arterial intima.

  1993cited by this paper
• Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury.

  1993cited by this paper
• Ambient oxygen tension modulates endothelial fibrinolysis.

  1993cited by this paper
• The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.

  1993cited by this paper
• Vascular Events in Placentae and Organ Allografts

  1992cited by this paper
• Microvascular Perturbations in Human Allografts: Analogies in Preeclamptic Placentae

  1992cited by this paper
• Transplant coronary disease: nonimmunologic risk factors.

  1992cited by this paper
• Hypertriglyceridemia and regulation of fibrinolytic activity.

  1992cited by this paper
• Cytokines as mediators of vascular pathology.

  1992cited by this paper
• Blood Coagulation, Fibrinolytic and Inhibitory Profiles in Renal Transplant Recipients: Comparison of Cyclosporine and Azathioprine

  1992cited by this paper
• Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.

  1991influential reference
• Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis.

  1991cited by this paper
• Mechanisms of neuronal adaptation to ethanol. Ethanol induces Hsc70 gene transcription in NG108-15 neuroblastoma x glioma cells.

  1991cited by this paper
• A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction.

  1990cited by this paper
• Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.

  1988cited by this paper
• Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.

  1987cited by this paper
• The human tissue plasminogen activator gene.

  1986cited by this paper
• Changes in size and secondary structure of the ribosomal transcription unit during vertebrate evolution.

  1975cited by this paper
• Detection of specific sequences among DNA fragments separated by gel electrophoresis.

  1975cited by this paper

• Plasminogen activator inhibitor-1 polymorphisms as a risk factor for chronic periodontitis in North Indian population.

  2019cites this paper
• Pediatric Heart Transplant in the United States: Current Status, Outcomes, and Ongoing Challenges

  2018cites this paper
• Cardiac allograft vasculopathy: Microvascular arteriolar capillaries ('capioles") and survival.

  2017cites this paper
• Cardiac Allograft Vasculopathy : Past , Present and Future !

  2016cites this paper
• Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis

  2014cites this paper
• Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease

  2014cites this paper
• Cardiac allograft vasculopathy: diagnosis, therapy, and

  2014cites this paper
• Biomarkers of heart transplant rejection: the good, the bad, and the ugly!

  2012cites this paper
• Pediatric coronary allograft vasculopathy--a review of pathogenesis and risk factors.

  2012cites this paper
• The role of fibrinolytic genes and proteins in the development of allograft vascular disease.

  2011cites this paper
• Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases

  2011cites this paper
• Blood management-issues: the panic of coagulopathic bleeding--is there a rational approach?

  2011cites this paper
• Early Prediction of Cardiac Allograft Vasculopathy and Heart Transplant Failure

  2011cites this paper
• The Effects of Pharmacologic Plasminogen Activator Inhibitor-1 Inhibition in Acute and Chronic Rejection in Murine Cardiac Allografts

  2011cites this paper
• Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis

  2009cites this paper
• PAI-1 gene: pharmacogenetic association of 4G/4G genotype with bleeding after cardiac surgery – pilot study

  2009cites this paper
• The effects of the combination of dietary flaxseed oil or fish oil with cyclosporine in a rat cardiac allograft model

  2008influential citation
• t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension

  2008cites this paper
• Distribution of —844 G/A and Hind III C/G PAI-1 Polymorphisms and Plasma PAI-1 Levels in Mexican Subjects: Comparison of Frequencies Between Populations

  2008cites this paper
• Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern.

  2007cites this paper
• Association of gene polymorphisms for plasminogen activators with alveolar bone loss.

  2007cites this paper
• Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery

  2006cites this paper
• The promise of protein-based and gene-based clinical markers in heart transplantation: from bench to bedside

  2006cites this paper
• Interleukin-6 polymorphism: a genetic risk factor for cardiac transplant related coronary vasculopathy?

  2005cites this paper
• The emergence of genomic and proteomic biomarkers in heart transplantation.

  2005cites this paper
• Surrogate Markers for Late Cardiac Allograft Survival

  2004cites this paper
• Endothelial Cell Biology: Inflammatory Biomarkers and Risk of Transplant Atherosclerosis

  2004cites this paper
• Thrombophiliediagnostik bei Empfängern von Organtransplantaten / Thrombophilia diagnostics in recipients of organ transplants

  2004cites this paper
• Population variability in some genes involving the haemostatic system: data on the general population of Corsica (France), Sardinia and Sicily (Italy)

  2004cites this paper
• Current status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest.

  2003cites this paper
• [Tissue plasminogen activator and plasminogen activator inhibitor gene polymorphisms: possible relation to atherosclerosis and its complications].

  2003cites this paper
• Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease.

  2003cites this paper
• Polimorfismes en gens de l'hemostasi. Estudi poblacional en la Mediterrània Occidental i associació amb risc per a la cardiopatia isquèmica.

  2002cites this paper
• Genetic variants of the hemostatic system and development of transplant coronary artery disease.

  2002cites this paper
• Update on cardiac allograft vasculopathy

  2002cites this paper
• Prothrombogenic microvasculature and transplant outcome

  2002influential citation
• Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies.

  2002cites this paper
• Microvascular prothrombogenicity and transplant coronary artery disease.

  2002cites this paper
• Elevated plasma tissue plasminogen activator and anti-THP-1 antibodies are independently associated with decreased graft survival in cardiac transplant recipients.

  2001cites this paper
• The early detection of patients at risk of developing transplant-associated CAD is a major step toward inter- vention with adequate therapies for preventing or miti- gating

  2001cites this paper
• Plasminogen Activator Inhibitor Type-1 (Part One): Basic Mechanisms, Regulation, and Role for Thromboembolic Disease

  2001cites this paper
• Vascular antithrombin and clinical outcome in heart transplant patients.

  2001cites this paper
• Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection

  2001cites this paper
• Genetic basis of procoagulant and fibrinolytic perioperative adverse events

  2001cites this paper
• Chronic rejection of transplanted hearts

  2001cites this paper
• Tissue-type Plasminogen Activator (tPA)

  2001cites this paper
• The clinical dilemma of cardiac allograft vasculopathy – an introduction to the clinical session

  2000cites this paper
• Transplant atherosclerosis: role of phenotypic modulation of vascular smooth muscle by nitric oxide.

  2000cites this paper
• Anticoagulation factors as predictors of transplant-associated coronary artery disease.

  2000cites this paper
• Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis.

  2000cites this paper
• Identification of the Hind III Polymorphic Site in the PAI-1 Gene: Analysis of the PAI-1 Hind III Polymorphism by PCR

  2000cites this paper
• Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation.

  2000cites this paper
• Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.

  1999cites this paper
• Relationship of fibrin deposition in microvasculature to outcomes in cardiac transplantation.

  1999cites this paper
• Expression of Plasminogen Activator Inhibitor Type I in Genotyped Human Endothelial Cell Cultures: Genotype-specific Regulation by Insulin

  1999cites this paper
• Genetics and molecular biology Structure and function of apolipoprotein A-I and high-density lipoprotein Review: (pp. 105±115)

  year unknowncites this paper